Bixiye
QP29-20 Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Peanut Allergy
Taariikhda uu dhaqangalayo Barnaamijka: Mar 25, 2020
Natiijooyinka Raadinta
Soo bandhiga 2761 - 2770 ee natiijooyinka 5041
Bixiye
QP30-20 MHCP Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Oxbryta™
Taariikhda uu dhaqangalayo Barnaamijka: Mar 25, 2020
Bixiye
QP31-20 Commercial Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Oxbryta™
Taariikhda uu dhaqangalayo Barnaamijka: Mar 25, 2020
Bixiye
QP27-20 Coronavirus (COVID-19) Information for Providers
Taariikhda uu dhaqangalayo Barnaamijka: Mar 11, 2020
Bixiye
2020 March Provider Press
Taariikhda uu dhaqangalayo Barnaamijka: 24, Feb 2020
Bixiye
QP8-20 Medical Drug Update for New to Market Golodirsen (Vyondys 53)
Taariikhda uu dhaqangalayo Barnaamijka: Jan 08, 2020
Bixiye
QP25-20 Pharmacy Benefit Exclusion for Injectafer®, Feraheme®, Venofer®, INFeD®, Ferrlecit®, and generic Ferrlecit®
Taariikhda uu dhaqangalayo Barnaamijka: Mar 11, 2020
Bixiye
QP26-20 CMS Decision Memo on Acupuncture for Chronic Low Back Pain
Taariikhda uu dhaqangalayo Barnaamijka: Mar 11, 2020
Bixiye
QP24-20 Pharmacy Benefit Update – Addition of Drugs to Existing Prior Authorization (PA) with Quantity Limit (QL) Programs
Taariikhda uu dhaqangalayo Barnaamijka: Mar 11, 2020
Bixiye
QP8R1-20 Update: Medical Drug Update for Golodirsen (Vyondys 53)
Taariikhda uu dhaqangalayo Barnaamijka: Mar 11, 2020